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Does Percutaneous Closure
of the Left Atrial Appendage
Prevent Stroke in Atrial Fibrillation?
With great interest we read the study by Ostermayer et al.
concerning percutaneous left atrial appendage (LAA) occlusion
using the PLAATO (percutaneous left atrial appendage trans-
catheter occlusion) system in 111 patients with atrial fibrillation
(AF) (1). Although this technique seems very attractive, several
concerns remain.
1. The investigators state that the PLAATO device has been
shown to be safe and effective in animal experiments. How-
ever, long-term results are still lacking because follow-up data in
6 of 25 dogs of the initial study have not yet been published (2).
2. Transient ischemic attack (TIA) or stroke or embolic risk
factors were criteria for patient inclusion. Thus, it remains
unclear why only stroke and not TIA was regarded a primary
or secondary end point. Were all patients investigated by a
neurologist to look for TIA and stroke at the follow-up visits?
3. When assessing angiographically the adequacy of LAA occlu-
sion, why did the researchers use the proximal and not the
distal dye flow, which appears to be the more logical approach?
Apparently both methods were used, but did they yield the
same results? Why was LAA occlusion assessed as “successful”
also in cases with “mild” or “trace” leaks? The investigators do
not exactly state in how many patients complete LAA occlu-
sion was achieved using the angiographic method.
4. Evaluating the adequacy of LAA occlusion by echocardiogra-
phy, it again remains unclear why mild and trace leaks were
defined as “successful” as it is known from surgical studies that
an incompletely occluded LAA may facilitate thrombus for-
mation and eventually embolism. The data do not show in how
many cases leak size increased, decreased, or if new leaks
developed. Did patients with leaks immediately after the
procedure or during follow-up receive oral anticoagulation?
Overall, complete LAA occlusion was present in only 35% of
patients at one month and 34% at six months, respectively.
5. The 6.6% annual mortality is quite high and exceeds the 4%
found in a previous observational AF study (3). An oversized
PLAATO device owing to its proximity may impair flow in
the circumflex branch of the left coronary artery. Furthermore,
the LAA has hemodynamic and endocrine properties, and
LAA elimination may aggravate heart failure (4). More de-
tailed information about the cardiac deaths, therefore, would
be desirable.
6. Despite “successful” LAA closure, two strokes and three TIAs
occurred. Thus, the annual event rate for stroke and TIA is
5.5%. Because AF is associated with a prothrombotic state (5),
just by closing the LAA not all sites of thrombus formation are
eliminated. In addition, one patient required surgery, and nine
procedure-related serious adverse events occurred in seven
patients, resulting in a complication rate of 6% to 7%.
Overall, the advantage of the PLAATO system in patients with
AF and a contraindication for anticoagulant therapy has not at all
been proven. Because long-term results are lacking, PLAATO at
present cannot be recommended as an alternative to oral anti-
coagulation in AF patients.
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REPLY
We appreciate the interest of Dr. Stöllberger and colleagues in
transcatheter left atrial appendage (LAA) occlusion using the
PLAATO (percutaneous left atrial appendage transcatheter occlu-
sion) system (1). They have raised a number of issues that are
answered below.
1. The 12-month results of the remaining six dogs that were still
alive at the time the initial animal experience was published
confirmed the short-term findings regarding clinical status,
and fluoroscopic, echocardiographic, and macroscopic exami-
nations (Nakai T, personal communication, August 28, 2005).
2. The intention of LAA occlusion is stroke prevention in atrial
fibrillation (AF) patients who are at high risk for ischemic
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stroke. Therefore, it seemed reasonable to determine stroke
as a primary end point. Both previous stroke and transient
ischemic attack (TIA) are accepted as independent risk factors
for stroke. We regarded stroke only as a primary end point
because the CHADS2 index (an acronym for congestive heart
failure, hypertension, age 75 years, diabetes mellitus, and
stroke or transient ischemic attack) estimates the expected
stroke and not TIA rate and because the assessment of stroke
compared to TIA is more objective (even though all patients
were seen by a neurologist).
3. The degree of LAA occlusion after device implantation was
evaluated by proximal dye flow. Distal dye injection in the
remaining part of the LAA was only performed before device
release and not systemically recorded. Although this method
provided important information on the ability of the device to
close off blood flow from the left atrium, it was not considered
exact because its position with attachment to the delivery
catheter was not the same as its final “released” position.
4. Left atrial appendage occlusion was defined “successful” not
only in cases with “absent leak” but also in cases with “mild” or
“trace” leak because we considered mild to trace leakage to be
too small for possible thrombi to exit the LAA, especially after
incorporation of the device into the LAA wall. The degree of
occlusion had no influence on a patient’s postprocedure med-
ication.
5. The primary aim of our present study was to show that LAA
occlusion using the PLAATO system can be performed at
acceptable risk. Definitive statements regarding annual mor-
tality and stroke prevention cannot be made owing to limited
follow-up. Nevertheless, we agree that the mortality was
higher in our patient population compared to the mortality of
a previously published study (2). Stöllberger et al. showed that
increased age was associated with mortality and stroke. Our
results confirm these findings. It is important to stress that our
patients had multiple additional risk factors and a contraindi-
cation for long-term warfarin treatment. Regarding the hemo-
dynamic properties of the LAA and the more detailed infor-
mation on cardiac deaths: none of these patients died from
congestive heart failure.
6. We agree that LAA occlusion is not a preventive strategy for
all cardioembolic events and that PLAATO at this point
cannot be recommended as an alternative to anticoagulation.
In the future, once further prospective studies are completed, it
may become an alternative for AF patients who are at increased
risk for stroke and who have a contraindication for long-term
anticoagulation treatment.
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